Company Overview of Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. researches, develops, manufactures, markets, and sells prescription pharmaceutical products. Its products include Vivelle-Dot and Estradot, which are transdermal estrogen patches; CombiPatch and Estalis, which are combination estrogen/progestogen patches; Stavzor, a delayed release valproic acid softgel; Pexeva, a paroxetine mesylate; Lithobid, a lithium carbonate; Brisdelle, a paroxetine capsule for the treatment of vasomotor symptoms associated with menopause; and estradiol transdermal system for the prevention of postmenopausal osteoporosis. It also manufactures Daytrana, a prescription central nervous system stimulant patch system for the treatment of ADHD in ...
11960 SW 144th Street
Miami, FL 33186
Founded in 1987
Key Executives for Noven Pharmaceuticals, Inc.
Chief Executive Officer and President
Chief Financial Officer, Principal Accounting Officer and Vice President
Vice President of Operations
Chief Scientific Officer and Vice President
Chief Medical Officer and Executive Vice President of Product Development
Compensation as of Fiscal Year 2015.
Noven Pharmaceuticals, Inc. Key Developments
Noven Pharmaceuticals, Inc. Presents at BIO-Europe 2015, Nov-02-2015
Oct 9 15
Noven Pharmaceuticals, Inc. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.
Noven Pharmaceuticals, Inc. Replaces Andrew Panagy with Scott Briggs as Vice President, Marketing & Sales
Mar 30 15
Noven Pharmaceuticals, Inc. announced the appointment of Scott Briggs as the company’s new Vice President, Marketing & Sales, succeeding Andrew Panagy, who is retiring. In this role, reporting to Jeffrey Eisenberg, the company’s President and Chief Executive Officer, Briggs is responsible for all marketing and sales activities at Noven and Noven Therapeutics (the company’s specialty pharmaceutical business unit). Prior to this appointment, he served as Vice President Women’s Health Sales for Noven Therapeutics, and as Noven’s Executive Director, Marketing and Managed Markets.
Noven Pharmaceuticals, Inc. Announces New 0.025 Mg/Day Dosage Strength for Minivelle
Feb 12 15
Noven Pharmaceuticals, Inc. announced that the new 0.025 mg/day dosage strength for Minivelle® (estradiol transdermal system) is now available by prescription nationwide for only the prevention of postmenopausal osteoporosis. The FDA initially approved Minivelle in October 2012 to treat moderate to severe vasomotor symptoms (VMS) due to menopause, commonly known as hot flashes. In September 2014, the FDA approved a new indication for prevention of postmenopausal osteoporosis for all doses of Minivelle. The new 0.025 mg/day low dose was approved for this indication only. The new 0.025 mg/day patch is 33% smaller than Minivelle 0.0375 mg/day, already about the size of a dime, making the 0.025 mg/day patch the world's smallest estrogen therapy patch ever. Minivelle is now available with five dosing options – 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day, with the newly available lower dose of 0.025 mg/day indicated for the prevention of postmenopausal osteoporosis only. The higher doses are indicated to treat moderate to severe VMS as well. If a patient uses Minivelle only to prevent osteoporosis from menopause, they should talk with their healthcare provider about whether a different treatment or medicine without estrogens might be better for them. Noven offers a savings program to help reduce Minivelle co-pays for eligible patients. On co-pays up to $70, patients pay no more than $15 for a one-month supply. On co-pays in excess of $70, patients may qualify for up to $55 in savings for a one-month supply. Patients can take advantage of this offer each month, for up to 12 uses.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|